ArticleEuropean archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery2026
HPV-specific treatment trends in oropharyngeal squamous cell carcinoma: a population-based analysis with stage-stratified interaction testing.
Article in European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeTo characterise population-level treatment trends in oropharyngeal squamous cell carcinoma (OPSCC) over 14 years and determine whether trends differ between p16-positive and p16-negative disease.
methodsWe analysed 66,394 OPSCC patients from SEER (2010-2023) for secular trend analysis, and 27,069 treated patients with confirmed squamous cell histology and documented p16/HPV status (2018-2023) for HPV-stratified and stage-stratified analyses. Cochran-Armitage trend tests, multivariable logistic regression, and formal HPV × year and stage × year interaction tests (likelihood ratio test), with Holm-Bonferroni correction for multiplicity, were employed.
resultsCRT increased from 52.6% to 59.9% and surgery declined from 39.0% to 29.5% over 2010-2023 (both p < 0.001). In HPV-stratified analysis, CRT increased significantly in both p16-positive (52.6% to 60.8%) and p16-negative patients (52.9% to 60.2%; both p < 0.001). Surgery declined in p16-positive patients (35.3% to 29.1%; p < 0.001) with a non-significant decline in p16-negative patients (31.0% to 27.7%; p = 0.051). After Holm-Bonferroni correction, only the surgery HPV × year interaction remained significant (adjusted p = 0.040); the CRT interaction did not (adjusted p = 0.185). Treatment shifts persisted across Stage I-II and Stage III-IV disease.
conclusionTreatment trends in OPSCC shifted substantially over the AJCC 8th Edition era. The decline in surgical treatment is HPV-specific and stage-independent; the rise in CRT is a broader trend affecting both HPV groups, though more pronounced in p16-positive disease. These findings underscore the importance of formal interaction testing and multiplicity correction when characterising subgroup-specific population trends.
Indexed as
Identifiers
42543416What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.